Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer

The primary objective of this study is to explore the efficacy and safety of adaptive therapy in the treatment of advanced breast cancer progressive after standard treatment.

Trial Details

NCT ID
NCT07088263
Phase
PHASE3
Sponsor
Sun Yat-sen University
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • Gemcitabine, Vinorelbine, Eribulin, or Utidelone
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • Understands and voluntarily signs the informed consent form.
  • ECOG PS of 0 or 1.
  • Expected survival: \>3 months
  • Histologically or cytologically confirmed advanced invasive breast cancer.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →